Published in Medical Letter on the CDC and FDA, July 17th, 2005
According to a study from the United States, "The U.S. Food and Drug Administration approved a meningococcal conjugate A/C/Y/W-135 vaccine (MCV-4) for use in persons aged 11 to 55 years in January, 2005; licensure for use in younger age groups is expected in 2 to 4 years.
"The study was done to evaluate and compare the projected health and economic impact of MCV-4 vaccination of U.S. adolescents, toddlers, and infants. Sensitivity analyses in which key input measures were varied over plausible ranges...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA